Zolmitriptan transdermal - Zosano Pharma

Drug Profile

Zolmitriptan transdermal - Zosano Pharma

Alternative Names: M 207; Triptan microneedle patch - Zosano Pharma; Triptan patch - Zosano Pharma; Triptan transdermal - Zosano Pharma; ZP triptan -Zosano Pharma; ZP-triptan

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Zosano Pharma
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Migraine

Most Recent Events

  • 05 Jan 2017 Zosano Pharma plans a safety study in Migraine
  • 08 Nov 2016 Zosano Pharma completes enrolment in its phase II/III Zotrip trial in Migraine in USA (Transdermal) (NCT02745392)
  • 17 Jun 2016 Phase-II/III clinical trials in Migraine in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top